Falade A G, Lagunju I A, Bakare R A, Odekanmi A A, Adegbola R A
Department of Pediatrics, University College Hospital and College of Medicine, University of Ibadan, Ibadan, Nigeria.
Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S190-6. doi: 10.1086/596500.
Streptococcus pneumoniae remains a major cause of childhood morbidity and mortality in the world. The introduction of pneumococcal conjugate vaccine in developing countries will be facilitated by a clearer understanding of the disease burden for bacterial causes of pneumonia and meningitis and the prevalent serotypes of S. pneumoniae.
We conducted a prospective, hospital-based surveillance for a 2-year period involving children aged 2-59 months at 3 urban hospitals in Ibadan, Nigeria, using standard microbiological methods with confirmation and further testing of isolates at the Medical Research Council Laboratories in The Gambia.
There were 1210 cases overall: 481 (39.8%) were meningitis, 399 (33.0%) were pneumonia, and 330 (27.2%) were bacteremia clinical syndromes. There were 24 cases of definite meningitis, of which 9 were caused by S. pneumoniae, 11 by Haemophilus influenzae type b, and 4 by Klebsiella species. Of the 90 culture-positive pneumonia cases, 9 were caused by S. pneumoniae, 2 by H. influenzae type b, and 79 by other species. Among cases of bacteremia, the pathogen isolation rate was 28.8% (95 of 330); the isolated species included S. pneumoniae (3 isolates), Staphylococcus aureus (20 isolates), Klebsiella species (13 isolates), Salmonella species (15 isolates), and Escherichia coli (6 isolates). Of the 23 S. pneumoniae isolates, 11 were serotyped; the serotypes found were 5 (5 isolates), 19F (3 isolates), and 4 (3 isolates), and 1 isolate was nontypeable. These isolates were all susceptible to penicillin. Eight of 9 patients with definite pneumococcal meningitis died, whereas all patients with pneumococcal pneumonia and septicemia survived.
Of the pneumococcal serotypes identified, 55% were covered by the licensed 7-valent pneumococcal conjugate vaccine, whereas all are covered by the 10- and 13-valent vaccines.
肺炎链球菌仍是全球儿童发病和死亡的主要原因。更清楚地了解细菌性肺炎和脑膜炎的疾病负担以及肺炎链球菌的流行血清型,将有助于在发展中国家推广肺炎球菌结合疫苗。
我们在尼日利亚伊巴丹的3家城市医院对2至59个月大的儿童进行了为期2年的前瞻性医院监测,采用标准微生物学方法,并在冈比亚的医学研究理事会实验室对分离株进行确认和进一步检测。
总共1210例病例:481例(39.8%)为脑膜炎,399例(33.0%)为肺炎,330例(27.2%)为菌血症临床综合征。有24例确诊脑膜炎,其中9例由肺炎链球菌引起,11例由b型流感嗜血杆菌引起,4例由克雷伯菌属引起。在90例培养阳性的肺炎病例中,9例由肺炎链球菌引起,2例由b型流感嗜血杆菌引起,79例由其他菌种引起。在菌血症病例中,病原体分离率为28.8%(330例中的95例);分离出的菌种包括肺炎链球菌(3株)、金黄色葡萄球菌(20株)、克雷伯菌属(13株)、沙门菌属(15株)和大肠杆菌(6株)。在23株肺炎链球菌分离株中,11株进行了血清分型;发现的血清型为5型(5株)、19F型(3株)和4型(3株),1株无法分型。这些分离株均对青霉素敏感。9例确诊肺炎球菌脑膜炎患者中有8例死亡,而所有肺炎球菌肺炎和败血症患者均存活。
在已鉴定的肺炎球菌血清型中,55%被许可的7价肺炎球菌结合疫苗覆盖,而所有血清型均被10价和13价疫苗覆盖。